ArticleFrontiers in oncology2025
Development and validation of a nomogram for predicting clinically significant prostate cancer using serologic indices, multiparametric magnetic resonance imaging, and sound touch elastography parameters: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate independent risk factors for clinically significant prostate cancer (csPCa) using serologic indices, multiparametric magnetic resonance imaging (mpMRI), and sound touch elastography (STE), and to develop and validate a nomogram-based prediction model using the optimal model derived from these factors. Methods: A total of 240 patients who underwent ultrasound-guided transperineal prostate biopsy at Anqing Municipal Hospital between January 2024 and December 2024 were retrospectively enrolled. After applying exclusion criteria, 160 patients were included in the modeling cohort, which was divided into clinically significant prostate cancer (csPCa) and non-clinically significant prostate cancer (non-csPCa) groups based on pathological results. Additionally, 40 eligible patients from December 2024 to February 2025 were selected as the external validation cohort. Baseline data of the modeling cohort were collected, and independent risk factors for csPCa were identified using univariate and multivariate logistic regression analyses. The optimal model was selected by comparing with single-modal models, followed by developing a Nomogram prediction model. R language was used to plot decision curve analysis (DCA) for clinical utility evaluation, while receiver operating characteristic (ROC) curve and calibration curve were employed to assess predictive performance. Results: Multivariate logistic regression analysis identified The Prostate Imaging Reporting and Data System score, age, free-to-total (f/t) prostate-specific antigen (PSA), Emax, TZ-ratio (transition zone ratio), and lesion density as independent risk factors for csPCa (all Conclusion: The nomogram model integrating serologic indices, multiparametric mpMRI, and STE provides a more accurate and reliable tool for diagnosing csPCa, demonstrating substantial potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.